HUTCHMED (China) Limited
http://www.hmplglobal.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HUTCHMED (China) Limited
EMA OKs First Drug To Prevent RSV Infection In Babies
A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.
ESMO: Positive Results Buoy Chinese Oncology Developers' Global Hopes
Promising new clinical results presented at ESMO are likely to help several Chinese firms gain traction to take their new drug candidates into global markets, including the US.
Trial Population Was One Reason For Pulling Surufatinib EU Filing
Hutchmed is in discussions with the European Medicines Agency on the path forward for its drug for advanced neuroendocrine tumors, whose marketing authorization application has now been withdrawn.
BeiGene/Novartis's Tislelizumab Faces US Delay Over China Inspection Challenges
An inability to conduct manufacturing field inspections in China due to strict local COVID-19 policies is cited as the only reason for the delay for the anti-PD-1 drug, for which the timescale for resolution is currently unclear.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Chi-Med
- Hutchison Whampoa
- Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited
- Hutchison China MediTech Limited